ANIX earnings date and last-quarter result: next report 2026-09-10, last quarter beat, P/E -11.80. Updated 2026-07-23.
Anixa Biosciences (ANIX) Research Hub
Anixa Biosciences (ANIX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 2.93 USD (-2.01%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -11.80, market cap 0.12B. This hub links to the full technical, earnings and options research available for ANIX.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 2.93 USD (-2.01%) |
| 52-week range | 2.36 USD – 3.89 USD |
| Trend regime | Range |
| 14-day RSI | 45.9 (Neutral) |
| Trailing P/E | -11.80 |
| Market cap | 0.12B |
| Dividend yield | 0.00% |
| Next earnings | 2026-09-10 |
Available research for ANIX
Covered Call on ANIX: how it works, illustrative setup around the real 2.93 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ANIX: how it works, illustrative setup around the real 2.93 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ANIX: how it works, illustrative setup around the real 2.93 USD price, max profit/loss, breakeven and when to use it. Educational.
ANIX technical analysis: range, last 2.93 USD, RSI 45.9, 52w range 2.36 USD–3.89 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is ANIX in?
Anixa Biosciences (ANIX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ANIX in an uptrend or downtrend?
As of 2026-10-26, ANIX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ANIX's trailing P/E ratio?
ANIX's trailing P/E is -11.80, with a market cap of 0.12B. See the earnings research page for full valuation detail.
When does ANIX next report earnings?
ANIX is next scheduled to report earnings on 2026-09-10.